Format

Send to

Choose Destination
Nat Rev Immunol. 2019 Sep;19(9):550-562. doi: 10.1038/s41577-019-0174-z.

Moving tuberculosis vaccines from theory to practice.

Author information

1
Center for Vaccine Research, Statens Serum Institut, Copenhagen, Denmark. pa@ssi.dk.
2
Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark. pa@ssi.dk.
3
South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa. thomas.scriba@uct.ac.za.

Abstract

Tuberculosis (TB) vaccine research has reached a unique point in time. Breakthrough findings in both the basic immunology of Mycobacterium tuberculosis infection and the clinical development of TB vaccines suggest, for the first time since the discovery of the Mycobacterium bovis bacillus Calmette-Guérin (BCG) vaccine more than a century ago, that a novel, efficacious TB vaccine is imminent. Here, we review recent data in the light of our current understanding of the immunology of TB infection and discuss the identification of biomarkers for vaccine efficacy and the next steps in the quest for an efficacious vaccine that can control the global TB epidemic.

PMID:
31114037
DOI:
10.1038/s41577-019-0174-z

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center